<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175901</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2014006</org_study_id>
    <nct_id>NCT02175901</nct_id>
  </id_info>
  <brief_title>Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication</brief_title>
  <official_title>Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No trial has examined the the efficacy of amoxicillin and metronidazole based quadruple
      therapy for Helicobacter pylori treatment. The study aims to compare the effectiveness and
      safety of 14-day amoxicillin-/metronidazole-based quadruple regiment and classical quadruple
      regiment for Helicobacter pylori eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori is the most successful human pathogen infecting an estimated 50% of the
      global population. It is a common and potentially curable cause of dyspepsia and peptic ulcer
      disease. Eradication in patients with peptic ulcer or even functional or non-investigated
      dyspepsia is a cost effective approach.

      Most Consensus Conferences and Clinical Guidelines recommend the prescription of a triple
      therapy including a proton pump inhibitor (PPI) and clarithromycin with either amoxicillin or
      metronidazole, as first-line treatment. However, the effectiveness of these triple-therapy
      regimens seems to have diminished over time, largely as a result of emerging resistance of
      the organism to clarithromycin. Due to the low efficacy achieved with these treatments, they
      have been deemed as unethical comparators in clinical trials. As antimicrobial resistance
      becomes more prevalent worldwide, treatment failure rates are likely to continue increasing,
      suggesting that new regimens for H pylori eradication must be sought.

      Bismuth-containing quadruple therapies have been used widely in H. pylori therapy with many
      permutations of doses and durations and with variable results. Classical bismuth-based
      quadruple therapy containing a PPI, bismuth, tetracycline and metronidazole has been
      recommended as the first-line treatment by the Maastricht IV Consensus Conference report and
      H. pylori Study Group of Chinese Society of Gastroenterology. But this regiment has high rate
      of side effects because of tetracycline. Standard triple therapy-based, bismuth-containing
      quadruple Therapy is also an alternative. Though addition bismuth and prolonging treatment
      duration can overcome H. pylori resistance to clarithromycin, its use as a first-line
      treatment is limited in areas of high clarithromycin resistance.

      Amoxicillin has low resistance rate as well as low percentage of side effects. The
      combination of amoxicillin and metronidazole in bismuth-containing quadruple therapy may be a
      better choice, which can avoid clarithromycin resistance and reduce side effects. Therefore,
      we will do a randomized trial to compare the eradication rate of 14-day amoxicillin and
      metronidazole based bismuth-containing quadruple therapy with amoxicillin and clarithromycin
      based quadruple therapy for Helicobacter pylori infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori</measure>
    <time_frame>2 months</time_frame>
    <description>Access eradication rate of H. pylori by intention to treat (ITT) and per-protocol (PP) analysis in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects of each treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Score side effects as mild, moderate or severe according to their influence on daily activities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal inhibitory concentrations (MIC) of antibiotics against each helicobacter pylori clinical isolate</measure>
    <time_frame>2 months</time_frame>
    <description>Determine MIC of amoxicillin, clarithromycin, and metronidazole by the twofold agar dilution method.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>antisecretory drug of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <other_name>proton pump inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>one component of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <other_name>Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>antibiotic of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>antibiotic of the amoxicillin/metronidazole-based quadruple therapy</description>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>antibiotic of the amoxicillin/clarithromycin-based quadruple therapy</description>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with non-investigated/functional dyspepsia or scarred peptic ulcer with
             indication of H pylori eradication treatment

          -  Ability and willingness to participate in the study and to sign and give informed
             consent

          -  confirmed H pylori infection by at least one of the following methods: C13-urea breath
             test, histology, rapid urease test or bacterial culture.

        Exclusion Criteria:

          -  patients with peptic ulcer

          -  previous H. pylori eradication therapy

          -  Age below 18 years

          -  major systemic diseases

          -  previous gastric surgery

          -  pregnancy or breastfeeding

          -  allergy to any of the study drugs

          -  receipt of anti-secretory therapy, antibiotics or bismuth salts 4 weeks prior to
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Renji Hospital, Shanghai Jiao-Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.</citation>
    <PMID>22491499</PMID>
  </reference>
  <reference>
    <citation>Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.</citation>
    <PMID>20557366</PMID>
  </reference>
  <reference>
    <citation>Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1134-40. doi: 10.1097/MEG.0b013e3283633b57. Review.</citation>
    <PMID>23778309</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hong Lu, MD</investigator_full_name>
    <investigator_title>Professor of GI Division</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori eradication</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

